Thus, we tested the hypothesis that the concerted molecular interplay between testosterone-associated HSD17B2, HSD17B3, SHBG, and SRD5A1 determine therapy response and susceptibility to disease relapse in patients with PCa. This evidence concerns the gene SRD5A1 and posterior cortical atrophy.